Skip to main content

Table 4 Response rates

From: Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study

 

Patients (n = 42)

Response (WHO criteria)

 

Complete

3 (7.1%)

Partial

12 (28.6%)

   Overall

 

   (Complete + Partial)

15 (35.7%)

Stable Disease

19 (45.2%)

Progressive Disease

6 (14.3%)

Missing data

2 (4.8%)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us